Request Demo
Pharmaceutical Insights
Navigate pharmaceutical trends with our insights on targets, institutional pipelines, clinical advances, and new drugs.
Recent blog posts
Latest Hotspot
8 min read
NCT07435324 Docetaxel Squamous Cell Carcinoma of Head and Neck Clinical Landscape Report 2026: Design, Endpoints, Sponsor and Readout Outlook
24 August 2026
NCT07435324 clinical trial report covering Docetaxel, Phase 3, endpoints, sponsor, geography, readout timing and development white space.
Latest Hotspot
8 min read
NCT07436741 Albumin-Bound Paclitaxel Pancreatic Cancer, Adult Clinical Landscape Report 2026: Design, Endpoints, Sponsor and Readout Outlook
24 August 2026
NCT07436741 clinical trial report covering Albumin-Bound Paclitaxel, Phase 3, endpoints, sponsor, geography, readout timing and development white space.
Latest Hotspot
8 min read
NCT07439133 XTR-004 Coronary Artery Disease Clinical Landscape Report 2026: Design, Endpoints, Sponsor and Readout Outlook
24 August 2026
NCT07439133 clinical trial report covering XTR-004, Phase 3, endpoints, sponsor, geography, readout timing and development white space.
Latest Hotspot
8 min read
NCT07436689 Levosimendan Pulmonary Arterial Hypertension Clinical Landscape Report 2026: Design, Endpoints, Sponsor and Readout Outlook
24 August 2026
NCT07436689 clinical trial report covering Levosimendan, Phase 3, endpoints, sponsor, geography, readout timing and development white space.
Latest Hotspot
8 min read
NCT07441291 Autologous CD19 CAR-T cells(Peking University People's Hospital) Ph-Like Acute Lymphoblastic Leukemia Clinical Landscape Report 2026: Design, Endpoints, Sponsor and Readout Outlook
24 August 2026
NCT07441291 clinical trial report covering Autologous CD19 CAR-T cells(Peking University People's Hospital), Phase 3, endpoints, sponsor, geography, readou
Latest Hotspot
8 min read
NCT07441317 RBD-7022 Mixed hyperlipidemia Clinical Landscape Report 2026: Design, Endpoints, Sponsor and Readout Outlook
24 August 2026
NCT07441317 clinical trial report covering RBD-7022, Phase 3, endpoints, sponsor, geography, readout timing and development white space.
Latest Hotspot
8 min read
NCT07435428 Botulinum toxin A(Medytox) Glabellar frown lines Clinical Landscape Report 2026: Design, Endpoints, Sponsor and Readout Outlook
24 August 2026
NCT07435428 clinical trial report covering Botulinum toxin A(Medytox), Phase 3, endpoints, sponsor, geography, readout timing and development white space.
Latest Hotspot
8 min read
NCT07438496 Nipocalimab-aahu Systemic Lupus Erythematosus Clinical Landscape Report 2026: Design, Endpoints, Sponsor and Readout Outlook
24 August 2026
NCT07438496 clinical trial report covering Nipocalimab-aahu, Phase 3, endpoints, sponsor, geography, readout timing and development white space.
Latest Hotspot
12 min read
Limb-Girdle Muscular Dystrophy Autosomal Recessive Indication Strategy Report 2026: Evidence, Targets, Competition and Market Outlook
24 August 2026
Evaluate Limb-Girdle Muscular Dystrophy in 2026: epidemiology, target biology, clinical competition, unmet need, deal activity and market attractiveness via Patsnap.
Latest Hotspot
12 min read
Corneal Dystrophy, Epithelial Basement Membrane Indication Strategy Report 2026: Evidence, Targets, Competition and Market Outlook
24 August 2026
Evaluate Corneal Dystrophy, Epithelial in 2026: epidemiology, target biology, clinical competition, unmet need, deal activity and market attractiveness via Patsnap.
Latest Hotspot
12 min read
Craniofacial Dysostosis Indication Strategy Report 2026: Evidence, Targets, Competition and Market Outlook
24 August 2026
Evaluate Craniofacial Dysostosis in 2026: epidemiology, target biology, clinical competition, unmet need, deal activity and market attractiveness via Patsnap MCP..
Latest Hotspot
12 min read
Familial Cold Autoinflammatory Syndrome 2 Indication Strategy Report 2026: Evidence, Targets, Competition and Market Outlook
24 August 2026
Evaluate Familial Cold Autoinflammatory in 2026: epidemiology, target biology, clinical competition, unmet need, deal activity and market attractiveness via Patsnap.